Home monitoring device aims to cut COPD hospitalizations by catching flare-ups early
NCT ID NCT07697105
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This trial tests whether a telemonitoring device called HCAlert can reduce hospitalizations and emergency visits for people with chronic obstructive pulmonary disease (COPD). Participants use the device at home to regularly measure their health, allowing doctors to spot worsening symptoms early. The study includes 340 adults with COPD who have had at least one flare-up in the past year. If successful, this approach could help patients manage their condition at home and avoid urgent care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- HCAlert medical telemonitoring device
- What this could lead to
- If effective, this telemonitoring program could help COPD patients avoid hospitalizations and emergency visits by detecting worsening symptoms early.
- What could go wrong
- This is a single study with 340 participants, and results may not apply to all COPD patients. The device requires daily use, which some may find burdensome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 340 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Nov 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female aged 18 years or older. * Patient with a confirmed diagnosis of chronic obstructive pulmonary disease (COPD), classified according to the GOLD ABE classification, who has experienced at least one COPD exacerbation within the previous 12 months. * Able and willing to provide written informed consent. * Able to comply with the telemonitoring procedures, including: * Performing physiological measurements on a regular basis; * Completing the required questionnaires. * Covered by a valid health insurance or social security scheme. Exclusion Criteria * Receiving long-term oxygen therapy (LTOT) or non-invasive ventilation (NIV), regardless of the duration since prescription. * Presence of severe, unstable comorbidities that may interfere with the study outcomes, including but not limited to: * Decompensated heart failure; * Chronic kidney disease; * Asthma; * Other restrictive pulmonary diseases; * Psychotic mental disorders. * Participation in another interventional clinical study within the month preceding enrollment or during the study period. * Unavailable for follow-up or planning to relocate before completion of study participation. * Protected populations, including: * Pregnant or breastfeeding women, or women planning to become pregnant during the study period. For women of childbearing potential not using effective contraception, pregnancy will be ruled out by a urine or blood human chorionic gonadotropin (hCG) test before enrollment. * Individuals deprived of liberty by judicial or administrative decision, or individuals under legal protection measures.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BPCO are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.